Literature DB >> 18273443

Splice variants of TLE family genes and up-regulation of a TLE3 isoform in prostate tumors.

Helder I Nakaya1, Felipe C Beckedorff, Maria L Baldini, Angela A Fachel, Eduardo M Reis, Sergio Verjovski-Almeida.   

Abstract

The TLE genes constitute a family of important transcriptional co-repressors involved in many cellular processes. We found evidence of alternatively spliced mRNAs for human TLE1-4 containing premature stop codons, thus encoding putative shortened proteins. Microarray experiments and Real-time RT-PCR assays showed that alternatively spliced isoforms of TLE1, TLE2 an d TLE3 were preferentially expressed in prostate in comparison to liver and kidney tissues. We identified by orientation-specific R T-PCR an antisense partially intronic non-coding RNA that overlaps a novel exon of the TLE3 gene, raising the possibility of regulation of alternative splicing by this non-coding transcript. The alternatively spliced isoform of TLE3 was up-regulated (6- to 17-fo ld) in prostate tumors in comparison to matched non-tumor adjacent tissue from 7 out of 11 (64%) patients and in four prostate tumor cell lines in comparison to a normal prostate cell line. These results demonstrate that different isoforms of TLE genes are commonly transcribed in human tissues and suggest that TLE3 could be involved in prostate cancer development.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18273443     DOI: 10.1016/j.bbrc.2007.10.097

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

1.  Transducin-Like Enhancer of Split 3 (TLE3) Expression Is Associated with Taxane Sensitivity in Nonserous Ovarian Carcinoma in a Three-Cohort Study.

Authors:  Brian Z Ring; Rajmohan Murali; Robert A Soslow; David D L Bowtell; Sian Fereday; Anna deFazio; Nadia Traficante; Catherine J Kennedy; Alison Brand; Raghwa Sharma; Paul Harnett; Goli Samimi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-03-12       Impact factor: 4.254

Review 2.  Alternative splicing within the Wnt signaling pathway: role in cancer development.

Authors:  B Sumithra; Urmila Saxena; Asim Bikas Das
Journal:  Cell Oncol (Dordr)       Date:  2016-01-13       Impact factor: 6.730

3.  Splice variants as novel targets in pancreatic ductal adenocarcinoma.

Authors:  Jun Wang; Laurent Dumartin; Andrea Mafficini; Pinar Ulug; Ajanthah Sangaralingam; Namaa Audi Alamiry; Tomasz P Radon; Roberto Salvia; Rita T Lawlor; Nicholas R Lemoine; Aldo Scarpa; Claude Chelala; Tatjana Crnogorac-Jurcevic
Journal:  Sci Rep       Date:  2017-06-07       Impact factor: 4.379

Review 4.  TLE1 function and therapeutic potential in cancer.

Authors:  Da Yuan; Xue Yang; Zhenpeng Yuan; Yanqing Zhao; Junchao Guo
Journal:  Oncotarget       Date:  2017-02-28

5.  Androgen-dependent alternative mRNA isoform expression in prostate cancer cells.

Authors:  Jennifer Munkley; Teresa M Maia; Nekane Ibarluzea; Karen E Livermore; Daniel Vodak; Ingrid Ehrmann; Katherine James; Prabhakar Rajan; Nuno L Barbosa-Morais; David J Elliott
Journal:  F1000Res       Date:  2018-08-03

6.  Transducin-like enhancer of split 3 regulates proliferation of melanoma cells via histone deacetylase activity.

Authors:  Masahiro Ogawa; Tatsuki Yaginuma; Chihiro Nakatomi; Tsuyoshi Nakajima; Yukiyo Tada-Shigeyama; William N Addison; Mariko Urata; Takuma Matsubara; Koji Watanabe; Kou Matsuo; Tsuyoshi Sato; Hiromi Honda; Hisako Hikiji; Seiji Watanabe; Shoichiro Kokabu
Journal:  Oncotarget       Date:  2019-01-08

7.  TLE3 as a candidate biomarker of response to taxane therapy.

Authors:  Swati A Kulkarni; David G Hicks; Nancy L Watroba; Christine Murekeyisoni; Helena Hwang; Thaer Khoury; Rodney A Beck; Brian Z Ring; Noel C Estopinal; Marshall T Schreeder; Robert S Seitz; Douglas T Ross
Journal:  Breast Cancer Res       Date:  2009-03-23       Impact factor: 6.466

8.  TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial.

Authors:  J M S Bartlett; T O Nielsen; D Gao; K A Gelmon; M A Quintayo; J Starczynski; L Han; M J Burnell; M N Levine; B E Chen; L E Shepherd; J W Chapman
Journal:  Br J Cancer       Date:  2015-08-18       Impact factor: 7.640

9.  The transcriptional co-repressor TLE3 suppresses basal signaling on a subset of estrogen receptor α target genes.

Authors:  Maïka Jangal; Jean-Philippe Couture; Stéphanie Bianco; Luca Magnani; Hisham Mohammed; Nicolas Gévry
Journal:  Nucleic Acids Res       Date:  2014-09-15       Impact factor: 16.971

10.  TLE3 represses colorectal cancer proliferation by inhibiting MAPK and AKT signaling pathways.

Authors:  Run-Wei Yang; Ying-Yue Zeng; Wen-Ting Wei; Yan-Mei Cui; Hui-Ying Sun; Yue-Long Cai; Xin-Xin Nian; Yun-Teng Hu; Yu-Ping Quan; Sheng-Lu Jiang; Meng Wang; Ya-Li Zhao; Jun-Feng Qiu; Ming-Xuan Li; Jia-Huan Zhang; Mei-Rong He; Li Liang; Yan-Qing Ding; Wen-Ting Liao
Journal:  J Exp Clin Cancer Res       Date:  2016-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.